(Q37695400)

22 August 2017

1 reference

title

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events (English)

1 reference

22 August 2017

0 references

John W Eikelboom

2

0 references

Graeme J. Hankey

object named as

Graeme J Hankey

series ordinal

1

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

273-284

1 reference

Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Triflusal for preventing serious vascular events in people at high risk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

1 reference

7 January 2021

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Parsing an enigma: the pharmacodynamics of aspirin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Antiplatelet drugs in cardiological practice: established strategies and new developments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

The net clinical benefit of warfarin anticoagulation in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Independent predictors of stroke in patients with atrial fibrillation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Current status of stroke risk stratification in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

New antithrombotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

The direct factor Xa inhibitor rivaroxaban.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970038-7

7 January 2021

10.1016/S1474-4422(10)70038-7

Identifiers

DOI

1 reference

22 August 2017

1 reference